CONTINUE TO SITE

OR WAIT null SECS

Expert on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL Management of Transplant-Ineligible Multiple Myeloma Register: Advances in the Treatment of Myelofibrosis Register: Improving Outcomes in Advanced Prostate Cancer Register: The Evolving HER2+ Metastatic Breast Cancer Treatment Landscape Taking a Patient-First Approach to Treatment in CLL Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

Expert on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCLManagement of Transplant-Ineligible Multiple MyelomaRegister: Advances in the Treatment of MyelofibrosisRegister: Improving Outcomes in Advanced Prostate CancerRegister: The Evolving HER2+ Metastatic Breast Cancer Treatment LandscapeTaking a Patient-First Approach to Treatment in CLLUpdates in Therapies of Relapsed and Refractory Follicular Lymphoma

Clinical

View More Brain Cancer Breast Cancer Colorectal Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Hematology Leukemia Lung Cancer Lymphoma Pediatric Cancers Skin Cancer

Brain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer

News

Clinical Topics Integrative Care All News

Clinical TopicsIntegrative CareAll News

Media

Around the Practice Between the Lines Clinical Consult Expert Interviews Medical World News OncView Podcasts Readout 360

Around the PracticeBetween the LinesClinical ConsultExpert InterviewsMedical World NewsOncViewPodcastsReadout 360

Conferences

Publications

All Journals For Authors Tumor Board

All JournalsFor AuthorsTumor Board

CME/CE

Resources

Contemporary Concepts Nurse Practitioners/Physician's Assistants Partners Sponsored

Contemporary ConceptsNurse Practitioners/Physician's AssistantsPartnersSponsored

eNewsletter Print Subscription

eNewsletterPrint Subscription

CureToday.com
OncLive.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Spotlight

Expert on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL
Management of Transplant-Ineligible Multiple Myeloma
Register: Advances in the Treatment of Myelofibrosis
Register: Improving Outcomes in Advanced Prostate Cancer
Register: The Evolving HER2+ Metastatic Breast Cancer Treatment Landscape
Taking a Patient-First Approach to Treatment in CLL
Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

ClinicalSee All >

Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer

CureToday.com
OncLive.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma

BCMA targeting agents such as the antibody-drug conjugate belantamab mafodotin show promise for heavily pretreated patients with relapsed/refractory multiple myeloma

New content coming soon, please check back later.